US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATYR PHARMA INC

3.47

+0.18505.64%

Volume:928.69K

Turnover:3.25M

Market Cap:307.90M

PE:-4.02

High:3.65

Open:3.33

Low:3.33

Close:3.28

Loading ...

Overview Company News Filings

aTyr Pharma Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $16

THOMSON REUTERS

Here's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation

Simply Wall St.

Several Insiders Invested In aTyr Pharma Flagging Positive News

Simply Wall St.

aTyr Pharma Initiated at Overweight by Cantor Fitzgerald

Cantor Fitzgerald Initiates aTyr Pharma at Overweight

MT Newswires Live

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57%

Simply Wall St.

aTyr Pharma Announces the Appointment of Eric Benevich to Its Board of Directors

THOMSON REUTERS

Press Release: aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

aTyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.

aTyr Pharma announces third positive DSMB review for efzofitimod

aTyr Pharma Inc: Dsmb Recommended That Study Continue Without Any Modifications

THOMSON REUTERS

aTyr Pharma Announces Third Positive Dsmb Review for Efzofitimod in Phase 3 Efzo-Fit™ Study in Pulmonary Sarcoidosis

THOMSON REUTERS

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

aTyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

aTyr Pharma Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.20 loss in 3Q 2023)

Simply Wall St.

aTyr Pharma Inc reports results for the quarter ended in September 30 - Earnings Summary

aTyr Pharma Q3 2024 GAAP EPS $(0.23) Misses $(0.22) Estimate

aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATYR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATYR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":3.465,"timestamp":1745345114370,"preClose":3.28,"halted":0,"volume":928687,"delay":0,"floatShares":81953560,"shares":88858612,"eps":-0.862131,"marketStatus":"Trading","change":0.185,"latestTime":"04-22 14:05:38 EDT","open":3.33,"high":3.6499,"low":3.33,"amount":3252419.3793152003,"amplitude":0.09753,"askPrice":3.47,"askSize":323,"bidPrice":3.46,"bidSize":695,"shortable":3,"etf":0,"ttmEps":-0.862131,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745352000000},"marketStatusCode":2,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":3.28,"preHourTrading":{"tag":"盘前","latestPrice":3.3307,"preClose":3.28,"latestTime":"09:29 EDT","volume":191,"amount":636.5203352,"timestamp":1745328544056},"postHourTrading":{"tag":"盘后","latestPrice":3.22,"preClose":3.28,"latestTime":"19:41 EDT","volume":335245,"amount":1099655.2556,"timestamp":1745278893009},"volumeRatio":1.375046,"impliedVol":0.9085,"impliedVolPercentile":0.3727},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","floatShares":81953560,"roa":"-39.03%","roe":"-79.88%","lyrEps":-0.862131,"volumeRatio":1.375046,"shares":88858612,"dividePrice":0,"high":3.6499,"amplitude":0.09753,"preClose":3.28,"low":3.33,"week52Low":1.42,"pbRate":"4.40","psRate":"1310.19","week52High":4.66,"institutionHeld":0,"latestPrice":3.465,"committee":0.365422,"eps":-0.862131,"divideRate":0,"volume":928687,"delay":0,"ttmEps":-0.862131,"open":3.33,"prevYearClose":3.62,"prevWeekClose":3.1,"prevMonthClose":3.02,"prevQuarterClose":3.02,"fiveDayClose":3.01,"twentyDayClose":3.7,"sixtyDayClose":3.59},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATYR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512715829","title":"aTyr Pharma Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2512715829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512715829?lang=en_us&edition=fundamental","pubTime":"2025-02-18 19:04","pubTimestamp":1739876691,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nFWN3P90AR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2507671393","title":"Here's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2507671393","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507671393?lang=en_us&edition=fundamental","pubTime":"2025-01-31 02:04","pubTimestamp":1738260249,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, aTyr Pharma  shareholders have done very well over the last year, with the share price soaring by 128%. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.So notwithstanding the buoyant share price, we think it's well worth asking whether aTyr Pharma's cash burn is too risky. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-watching-atyr-180409736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","BK4588","PSQ","QLD","NDAQ","IE00BGHQF748.EUR","TSYW.SI","BK4112","USJW.SI","TQQQ","IE00BKPKM429.USD","BK4139","BK4585","USAW.SI","NQmain","NVIW.SI","IE00B3QW5Z07.USD","LU2210149790.SGD","MNQmain","ATYR","QID","IE00B64PRP62.GBP","LU2210150020.SGD",".IXIC","SQQQ"],"gpt_icon":1},{"id":"2502845856","title":"Several Insiders Invested In aTyr Pharma Flagging Positive News","url":"https://stock-news.laohu8.com/highlight/detail?id=2502845856","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502845856?lang=en_us&edition=fundamental","pubTime":"2025-01-10 18:20","pubTimestamp":1736504400,"startTime":"0","endTime":"0","summary":"When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in aTyr Pharma, Inc.'s  instance, it's good news for shareholders.Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.The Last 12 Months Of Insider Transactions At aTyr Pharma. Over the last year, we can see that the biggest insider purchase was by Independent Director Paul Schimmel for US$185k worth of shares, at about US$1.93 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$3.74. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.While aTyr Pharma insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions  over the last year. If you want to know exactly who sol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/several-insiders-invested-atyr-pharma-102000721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ATYR"],"gpt_icon":1},{"id":"2501259168","title":"aTyr Pharma Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2501259168","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501259168?lang=en_us&edition=fundamental","pubTime":"2025-01-06 23:53","pubTimestamp":1736178780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATYR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2025 10:53 ET (15:53 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2501237315","title":"Cantor Fitzgerald Initiates aTyr Pharma at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2501237315","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501237315?lang=en_us&edition=fundamental","pubTime":"2025-01-06 22:05","pubTimestamp":1736172359,"startTime":"0","endTime":"0","summary":"aTyr Pharma (ATYR) has an average rating of buy and mean price target of $20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATYR"],"gpt_icon":0},{"id":"2492441876","title":"Exploring Three High Growth Tech Stocks In The United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2492441876","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492441876?lang=en_us&edition=fundamental","pubTime":"2024-12-20 22:06","pubTimestamp":1734703573,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has experienced a 3.5% drop, yet it has shown resilience with a 22% rise over the past year and an anticipated annual earnings growth of 15%. In this dynamic environment, identifying high-growth tech stocks involves assessing their potential to capitalize on technological advancements and market trends while aligning with robust growth forecasts.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener.Overview: aTyr Pharma, Inc. is a biotherapeutics company focused on discovering and developing medicines targeting novel immunological pathways in the United States, with a market capitalization of $264.42 million.Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for high unmet medical needs globally, with a market capitalization of approximately $265.30 million.Operations: Va","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-three-high-growth-tech-140613251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ATYR","BK4211","KNSA","VNDA","UBCP"],"gpt_icon":1},{"id":"2492179022","title":"aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492179022","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492179022?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:06","pubTimestamp":1734617194,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies aTyr Pharma's stock price is sensitive to their trading actions. 50% of the business is held by the top 8 shareholders. Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business. If you want to know who really controls aTyr Pharma, Inc. , then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 57% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises .Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute.Let's take a closer look to see what the different types of shareholders can tell us about aTyr Pharma.While it makes sense to study institut","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-inc-nasdaq-atyr-140634596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210149790.SGD","BK4139","SQQQ","NDAQ",".IXIC","TQQQ","BK4588","QID","BK4585","USAW.SI","IE00B64PRP62.GBP","NVIW.SI","USJW.SI","QLD","MNQmain","IE00BKPKM429.USD","TSYW.SI","ATYR","LU2095319765.USD","PSQ","NQmain","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2491354393","title":"aTyr Pharma Announces the Appointment of Eric Benevich to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2491354393","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491354393?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:00","pubTimestamp":1734037200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUA2QDLWT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2491735435","title":"Press Release: aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2491735435","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491735435?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:00","pubTimestamp":1734037200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Dec. 12, 2024  -- aTyr Pharma, Inc.  , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company's Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. .\"We are excited to welcome Eric Benevich to the Board of Directors,\" said Timothy P. Coughlin, Chairman of the Board of aTyr. \"His extensive background bringing new products to market and the knowledge and expertise he has gained from both building and leading commercial activities at biopharmaceutical companies will be an invaluable resource as aTyr continues its evolution towards commercialization.\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","ATYR","BK4232","BK4022","BK4139"],"gpt_icon":0},{"id":"2490049867","title":"aTyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2490049867","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490049867?lang=en_us&edition=fundamental","pubTime":"2024-12-11 01:28","pubTimestamp":1733851680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATYR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2024 12:28 ET (17:28 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2490610018","title":"aTyr Pharma announces third positive DSMB review for efzofitimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2490610018","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490610018?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:15","pubTimestamp":1733836559,"startTime":"0","endTime":"0","summary":"aTyr Pharma (ATYR) announced the outcome of a third, pre-planned interim safety analysis conducted by an independent data and safety monitoring boa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-announces-third-positive-dsmb-review-for-efzofitimod?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-announces-third-positive-dsmb-review-for-efzofitimod?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2490473090","title":"aTyr Pharma Inc: Dsmb Recommended That Study Continue Without Any Modifications","url":"https://stock-news.laohu8.com/highlight/detail?id=2490473090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490473090?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:01","pubTimestamp":1733835712,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nFWN3NB0G4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2490090445","title":"aTyr Pharma Announces Third Positive Dsmb Review for Efzofitimod in Phase 3 Efzo-Fit™ Study in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2490090445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490090445?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:01","pubTimestamp":1733835712,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nFWN3NB0G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2490724575","title":"aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2490724575","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490724575?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:00","pubTimestamp":1733749200,"startTime":"0","endTime":"0","summary":"ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism to reduce fibrosis and fibrotic markers in models of lung and kidney fibrosis.ATYR0101 is a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase  that binds to latent transforming growth factor beta binding protein 1  to induce myofibroblast apoptosis.“We are excited by these findings that further demonstrate the way in which ATYR0101 binds a known fibrosis target with pronounced effects in preclinical models of lung and renal fibrosis,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “These findings suggest that ATYR0101 has the potential to be a next generation anti-fibrotic for lung and kidney fibrosis with a differentiated mechanism of action compared to current standard of care that could potentially treat advanced fibrotic conditions.”","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7zmU14QtH6iCLlECQzM6Iw--~B/aD03NjQ7dz0xMjc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e157a9140724ca1e2319b3702b03b319","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7zmU14QtH6iCLlECQzM6Iw--~B/aD03NjQ7dz0xMjc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e157a9140724ca1e2319b3702b03b319"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-present-preclinical-research-130000266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATYR"],"gpt_icon":0},{"id":"2488692575","title":"aTyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2488692575","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488692575?lang=en_us&edition=fundamental","pubTime":"2024-12-04 01:28","pubTimestamp":1733246880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATYR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2024 12:28 ET (17:28 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2483375661","title":"aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2483375661","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483375661?lang=en_us&edition=fundamental","pubTime":"2024-11-15 21:00","pubTimestamp":1731675600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov. 15, 2024  -- aTyr Pharma, Inc.  , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December 8 – 11, 2024, in Whistler, British Columbia, Canada.Details of the presentations appear below. The posters will be available on the aTyr website once presented.Title:Anti-Fibrotic Activity Observed Across Preclinical Models of Pulmonary and Renal Fibrosis for a Potential Therapeutic Based on Asp-tRNA SynthetaseAuthors: Alison Barber, Clara Polizzi, Jasmine Stamps, Max Pastenes, Ryan A. Adams, Christoph Burkart, Leslie Nangle. aTyr Pharma, San Diego, CA.Poster Number: 1045Session: Poster Session #1Date and Time: Monday, December 9, 2024, at 7:30 p.m. ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7zmU14QtH6iCLlECQzM6Iw--~B/aD03NjQ7dz0xMjc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e157a9140724ca1e2319b3702b03b319","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7zmU14QtH6iCLlECQzM6Iw--~B/aD03NjQ7dz0xMjc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e157a9140724ca1e2319b3702b03b319"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-present-posters-trna-130000062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2482600172","title":"aTyr Pharma Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.20 loss in 3Q 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482600172","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482600172?lang=en_us&edition=fundamental","pubTime":"2024-11-10 21:46","pubTimestamp":1731246408,"startTime":"0","endTime":"0","summary":"aTyr Pharma ( NASDAQ:ATYR ) Third Quarter 2024 Results Key Financial Results Net loss: US$17.3m (loss widened by 52...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atyr/atyr-pharma/news/atyr-pharma-third-quarter-2024-earnings-us023-loss-per-share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ATYR"],"gpt_icon":0},{"id":"2481118546","title":"aTyr Pharma Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481118546","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481118546?lang=en_us&edition=fundamental","pubTime":"2024-11-08 13:06","pubTimestamp":1731042418,"startTime":"0","endTime":"0","summary":"* aTyr Pharma Inc    reported a quarterly adjusted loss of 23 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -20 cents.  Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2481013150","title":"aTyr Pharma Q3 2024 GAAP EPS $(0.23) Misses $(0.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481013150","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481013150?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:58","pubTimestamp":1731016697,"startTime":"0","endTime":"0","summary":"aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41826914/atyr-pharma-q3-2024-gaap-eps-0-23-misses-0-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"aTyr Pharma Q3 2024 GAAP EPS $(0.23) Misses $(0.22) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2481315169","title":"aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481315169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481315169?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:01","pubTimestamp":1731013261,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUACBXZCY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATYR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-13","symbol":"ATYR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2024-11-07","symbol":"ATYR","fiscalQuarterEnding":"2024/09","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2024-08-13","symbol":"ATYR","fiscalQuarterEnding":"2024/06","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2024-05-02","symbol":"ATYR","fiscalQuarterEnding":"2024/03","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714622400000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2024-03-14","symbol":"ATYR","fiscalQuarterEnding":"2023/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710388800000,"reportTimeType":"post","actualEps":-0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATYR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATYR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1818,"buy":0.8182,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8182,"analysts":11,"updateTime":1740196800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ATYR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ATYR","date":"2025-04-21","current":-4.302543,"percent":0.368687,"low":-5.827142,"twenty":-4.722221,"median":-4.038222,"eighty":-2.416702,"high":-1.932291,"avg":-3.691407,"sd":1.09573,"marketCap":275461697},"quantilePoints":[{"date":"2024-06-07","current":-2.380173,"twenty":-2.380173,"median":-2.380173,"eighty":-2.380173,"marketCap":128360348},{"date":"2024-06-14","current":-2.367376,"twenty":-2.482546,"median":-2.431359,"eighty":-2.377614,"marketCap":127670239},{"date":"2024-06-21","current":-2.021867,"twenty":-2.446715,"median":-2.367376,"eighty":-2.203579,"marketCap":109037285},{"date":"2024-06-28","current":-1.970681,"twenty":-2.431359,"median":-2.367376,"eighty":-2.111444,"marketCap":106276847},{"date":"2024-07-05","current":-1.970681,"twenty":-2.431359,"median":-2.265003,"eighty":-1.991155,"marketCap":106276847},{"date":"2024-07-12","current":-2.073054,"twenty":-2.39041,"median":-2.092249,"eighty":-1.970681,"marketCap":111797722},{"date":"2024-07-15","current":-2.226613,"twenty":-2.380173,"median":-2.111444,"eighty":-1.970681,"marketCap":120079035},{"date":"2024-08-02","current":-2.495343,"twenty":-2.421122,"median":-2.130639,"eighty":-1.9758,"marketCap":134571333},{"date":"2024-08-09","current":-2.380173,"twenty":-2.403207,"median":-2.265003,"eighty":-1.996274,"marketCap":128360348},{"date":"2024-08-16","current":-2.618312,"twenty":-2.418704,"median":-2.296995,"eighty":-2.001393,"marketCap":151592396},{"date":"2024-08-23","current":-2.448121,"twenty":-2.445503,"median":-2.341783,"eighty":-2.021867,"marketCap":141738890},{"date":"2024-08-30","current":-2.474305,"twenty":-2.468042,"median":-2.373775,"eighty":-2.032104,"marketCap":143254814},{"date":"2024-09-06","current":-2.291023,"twenty":-2.461213,"median":-2.354579,"eighty":-2.073054,"marketCap":132643346},{"date":"2024-09-13","current":-2.448121,"twenty":-2.474305,"median":-2.380173,"eighty":-2.111444,"marketCap":141738890},{"date":"2024-09-20","current":-2.448121,"twenty":-2.474305,"median":-2.399368,"eighty":-2.149834,"marketCap":141738890},{"date":"2024-09-27","current":-2.277931,"twenty":-2.474305,"median":-2.382664,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-04","current":-2.277931,"twenty":-2.469749,"median":-2.373775,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-11","current":-2.77541,"twenty":-2.474305,"median":-2.382664,"eighty":-2.251748,"marketCap":160687939},{"date":"2024-10-18","current":-3.469263,"twenty":-2.48085,"median":-2.399368,"eighty":-2.251748,"marketCap":200859924},{"date":"2024-10-25","current":-4.241665,"twenty":-2.500488,"median":-2.421938,"eighty":-2.265003,"marketCap":245579681},{"date":"2024-10-31","current":-4.097658,"twenty":-2.555472,"median":-2.431359,"eighty":-2.275241,"marketCap":237242099},{"date":"2024-11-08","current":-4.058383,"twenty":-2.922036,"median":-2.441575,"eighty":-2.277905,"marketCap":234968213},{"date":"2024-11-15","current":-3.78886,"twenty":-3.621287,"median":-2.448121,"eighty":-2.277931,"marketCap":241789871},{"date":"2024-11-22","current":-3.919838,"twenty":-3.629704,"median":-2.448121,"eighty":-2.277931,"marketCap":250148372},{"date":"2024-11-29","current":-4.643298,"twenty":-3.916561,"median":-2.461213,"eighty":-2.285786,"marketCap":296316696},{"date":"2024-12-06","current":-4.301299,"twenty":-4.007344,"median":-2.474305,"eighty":-2.298878,"marketCap":274491670},{"date":"2024-12-13","current":-3.972453,"twenty":-4.100191,"median":-2.474305,"eighty":-2.31136,"marketCap":253506069},{"date":"2024-12-20","current":-4.143453,"twenty":-4.111931,"median":-2.474305,"eighty":-2.3168,"marketCap":264418582},{"date":"2024-12-27","current":-4.95899,"twenty":-4.144489,"median":-2.487396,"eighty":-2.317206,"marketCap":316462874},{"date":"2025-01-03","current":-5.143143,"twenty":-4.229494,"median":-2.500488,"eighty":-2.317206,"marketCap":328214811},{"date":"2025-01-10","current":-4.919528,"twenty":-4.267848,"median":-2.526671,"eighty":-2.317206,"marketCap":313944602},{"date":"2025-01-17","current":-4.932682,"twenty":-4.327606,"median":-2.579037,"eighty":-2.328986,"marketCap":314784026},{"date":"2025-01-24","current":-4.682759,"twenty":-4.341161,"median":-2.768865,"eighty":-2.330035,"marketCap":298834968},{"date":"2025-01-31","current":-4.919528,"twenty":-4.389843,"median":-2.932509,"eighty":-2.330297,"marketCap":313944602},{"date":"2025-02-07","current":-5.090528,"twenty":-4.509129,"median":-3.510289,"eighty":-2.339486,"marketCap":324857115},{"date":"2025-02-14","current":-4.722221,"twenty":-4.606467,"median":-3.575068,"eighty":-2.341783,"marketCap":301353241},{"date":"2025-02-21","current":-5.827142,"twenty":-4.643298,"median":-3.6107,"eighty":-2.357139,"marketCap":371864863},{"date":"2025-02-28","current":-5.090528,"twenty":-4.682759,"median":-3.851618,"eighty":-2.375054,"marketCap":324857115},{"date":"2025-03-07","current":-4.051376,"twenty":-4.682759,"median":-3.972453,"eighty":-2.380173,"marketCap":258542613},{"date":"2025-03-14","current":-5.248373,"twenty":-4.682759,"median":-3.985607,"eighty":-2.381668,"marketCap":334930203},{"date":"2025-03-21","current":-4.929845,"twenty":-4.727483,"median":-3.990774,"eighty":-2.382664,"marketCap":315623450},{"date":"2025-03-28","current":-4.52461,"twenty":-4.75379,"median":-4.035211,"eighty":-2.388848,"marketCap":289679075},{"date":"2025-04-04","current":-3.872289,"twenty":-4.740636,"median":-4.038222,"eighty":-2.400648,"marketCap":247915527},{"date":"2025-04-11","current":-3.802893,"twenty":-4.727483,"median":-4.011134,"eighty":-2.407615,"marketCap":243472596},{"date":"2025-04-17","current":-4.191509,"twenty":-4.722221,"median":-4.035211,"eighty":-2.414083,"marketCap":268353008},{"date":"2025-04-21","current":-4.302543,"twenty":-4.722221,"median":-4.038222,"eighty":-2.416702,"marketCap":275461697}],"updateTime":1745320806575}}}